FindTrial
Sign In

Continuous Versus Intermittent Nebulization Therapy in Acute asthma exacerbation at Emergency department

Continuous Versus Intermittent Nebulization Therapy in Acute asthma exacerbation at Emergency department: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250918001
Enrollment
80
Registered
2025-09-18
Start date
2024-11-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute asthma exacerbation Asthma exacerbation, Continuous nebulization therapy, Intermittent nebulization therapy, Budesonide, Berodual, Emergency department

Interventions

MiniHEART-HiFlo nebulizer, The chamber was filled with budesonide 1000 microgram/2 mL, totaling 6 mL (3 respules), combined with fenoterol 1.25 mg and ipratropium bromide 0.5 mg (Berodual, 4 mL), tota
Experimental Device,Active Comparator Device
Continuous nebulization therapy ,Intermittent nebulization therapy

Sponsors

the Subcommittee on Research Grant Consideration and Promotion, Thammasat University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults aged >18 years with clinical presentation consistent with acute asthma exacerbation, including: Dyspnea,Tachypnea, Chest tightness, Cough, Wheezing

Exclusion criteria

Exclusion criteria: 1.Respiratory failure requiring immediate intubation, 2.Facial abnormalities preventing mask fitting (deformity, severe facial skin infection), 3.Patients with tracheostomy, 4.History of allergy to corticosteroids or beta2-agonists, 5.Suspected COVID19 infection under investigation (PUI), 6.Suspected or confirmed pulmonary tuberculosis, 7.Inability to perform pulmonary function testing (spirometry or peak expiratory flow)

Design outcomes

Primary

MeasureTime frame
Length of stay in the emergency department (ED LOS) 24 hours Hour,Pulmonary function improvement 24 hours Peak Expiratory Flow (PEF) and Forced Expiratory Volume in 1 second (FEV1),Dyspnea severity 24 hours Borg dyspnea scale—

Secondary

MeasureTime frame
Proportion of patients discharge home from ED 8 hours proportion,Length of hospital stay (LOS) 2 weeks days,Need for endotracheal intubation 2 weeks Binary outcome,Revisit with asthma exacerbation within 48 hours 48 hours hours—

Countries

Thailand

Contacts

Public ContactChayanuch Thanalearkchai

Department of Emergency Medicine, Faculty of Medicine, Thammasat University

think.thana@gmail.com0816566696

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026